Key result
Risdiplam treatment produced a dose-dependent, median twofold increase in blood SMN protein within 4 weeks that was sustained over 24 months.
Why the study?
Spinal muscular atrophy is caused by reduced survival of motor neuron (SMN) protein levels, and the appropriate dose of the SMN2 pre-mRNA splicing modifier risdiplam needed to be identified for a pivotal trial.
Does risdiplam increase functional SMN protein and demonstrate safety in individuals with types 2 and 3 spinal muscular atrophy?
RCT (n=51)
double-blind
2:1
Does risdiplam increase functional SMN protein and demonstrate safety in individuals with types 2 and 3 spinal muscular atrophy?
Risdiplam safely increased blood SMN protein levels twofold in patients with types 2 and 3 SMA, establishing the dose for the pivotal phase 2 trial.
Answers are grounded in this paper and cite their sources.
Supports risdiplam dose selection for pivotal SMA trials; extends pharmacodynamic data for SMN modulators in types 2/3 disease.
BACKGROUND AND PURPOSE: Spinal muscular atrophy (SMA) is caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations in the SMN1 gene. Risdiplam is an orally administered molecule that modifies SMN2 pre-mRNA splicing to increase functional SMN protein. METHODS: SUNFISH Part 1 was a dose-finding study conducted in 51 individuals with types 2 and 3 SMA aged 2-25 years. A dose-escalation method was used to identify the appropriate dose for the subsequent pivotal Part 2. Individuals were randomized (2:1) to risdiplam or placebo at escalating dose levels for a minimum 12-week, double-blind, placebo-controlled period, followed by treatment for 24 months. The dose selection for Part 2 was based on safety, tolerability, pharmacokinetic, and pharmacodynamic data. Exploratory efficacy was also measured. RESULTS: There was no difference in safety findings for all assessed dose levels. A dose-dependent increase in blood SMN protein was observed; a median twofold increase was obtained within 4 weeks of treatment initiation at the highest dose level. The increase in SMN protein was sustained over 24 months of treatment. Exploratory efficacy showed improvement or stabilization in motor function. The pivotal dose selected for Part 2 was 5 mg for patients with a body weight ≥20 kg or 0.25 mg/kg for patients with a body weight <20 kg. CONCLUSIONS: SUNFISH Part 1 demonstrated a twofold increase in SMN protein after treatment with risdiplam. The observed safety profile supported the initiation of the pivotal Part 2 study. The long-term efficacy and safety of risdiplam are being assessed with ongoing treatment.
No takes yet. Share an insight, caveat, or question.
Mercuri et al. (2022) conducted an RCT in types 2 and 3 spinal muscular atrophy (n=51). Risdiplam vs. Placebo was evaluated on Blood SMN protein levels. Risdiplam treatment produced a dose-dependent, median twofold increase in blood SMN protein within 4 weeks that was sustained over 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: